Introduction
Dilated cardiomyopathy is a common disorder characterized by left ventricular enlargement and reduced systolic function. In the absence of an identifiable cause, DCM is labeled idiopathic. 1 Approximately 25-50% of DCM cases initially diagnosed as idiopathic are familial, suggesting a genetic etiology. 2, 3 Over 30 genes have been linked to familial DCM and the disorder is most often has autosomal dominant inheritance. There is considerable genetic heterogeneity, and implicated genes encode proteins subserving a range of functions, such as sarcomeric or cytoskeletal integrity, ion transport, and nuclear membrane or mitochondrial function. 4, 5 However, the genetic basis of most cases of familial DCM is currently unknown. Commercial testing that surveys coding regions and splice sites of the most common known DCM genes will not detect variants in genes that are novel or rarely implicated, and the sensitivity of commercial testing for identification of a causal variant is approximately 35%. 6 The coding portion of the genome, or exome, is 1-3% of the genome, but contains a majority of the alleles underlying known monogenic disorders, and therefore represents a highly enriched target for identifying disease-causing genes. 7 Advances in next generation sequencing have made WES a viable, powerful approach to study Mendelian disorders. [8] [9] [10] In the present study, WES was performed in a large, multiplex family with familial DCM of unknown cause.
We describe how analyzing exome sequence data from distantly related individuals in the kindred, in conjunction with internally generated reference exome sequences, allowed identification of a causative variant in RBM20.
Methods
We hypothesized that any causative familial mutation would be novel or rare, as the proband had previously undergone negative commercial screening (CardioChip, Laboratory for Molecular ondrial function. members of the pedigree obligatorily carry the culprit mutation, and more distant relatives share a smaller fraction of the genome, we reasoned that only three remotely related, affected individuals was sufficient to identify the causal variant by WES followed by systematic filtering on rarity, functional significance and evolutionary conservation. To further narrow the list of candidates, shared variants were filtered against exomes of internal references that were analyzed for a separate project on drug-induced arrhythmia. Additionally, the bioinformatic tool VAAST was applied to help identify the causal variant in this pedigree.
Subjects
Subjects were enrolled from the Vanderbilt Center for Inherited Heart Disease (CIHD) into the Vanderbilt Heart and Vascular Institute Main Heart Registry and provided written informed consent. The Institutional Review Board of Vanderbilt University approved the study protocol.
Clinical parameters of evaluated subjects are in ate e e p p p project on dr dr drug--in n n ndu u duce ce ce c d ar a arr rh r yt y ythm m mia a. A Ad ddit it itio io iona na n n lly y y, t the b b bi i ioin in nf f fo f rm m m mat at atic c c t t tool l l l V V VA d to h h h hel l el elp p p p id id iden nti ti tify f fy fy t t the he h c causa sa al l l l v varian an nt t t in in in in t thi hi hi his s pe pedi di dig gr gr gree ee ee. not directly evaluated were deemed affected if there was a history of heart failure or unexplained sudden death prior to the age of 50 years. Those reported to be well or known to have had noncardiac death were considered unaffected. Indeterminate status was assigned to subjects with onset of heart failure or sudden death after the age of 50. In the absence of reliable family history, subjects were assigned and affection status of unknown. The pedigree is shown in Figure 1 .
Whole Exome Sequencing of Distantly Related Individuals
Subjects were sequenced in collaboration with the Genome Institute of Washington University at St. Louis. WES was performed on the proband and two affected relatives: a third cousin and a third cousin once removed. The three individuals were expected to share <0.1% of their genomes identical by descent. Targeted capture was performed using the NimbleGen SeqCap EZ Exome v2.0 enrichment probe library providing coverage of 44.1 Mb of genomic sequence, including over 30,000 genes and approximately 300,000 associated exons. 11 Sequencing was performed on the Illumina HiSeq 2000 platform with paired end 100 base pair reads. Reads were aligned to the human reference sequence hg19 using the Burrows-Wheeler Aligner (BWA). 12 Duplicate reads were marked using the Picard MarkDuplicates Tool, 13 and the Genome Analysis ToolKit (GATK) was used for base recalibration, local realignment, duplicate removal, and single nucleotide polymorphism (SNP) calling. In addition to the default settings of the GATK best practices v.3, we also applied the following hard filters to eliminate lowfidelity calls: |DP<5| (calls with absolute depth <5) and |GQ<10| (calls with genotype quality score <10). Annotation was performed using Seattle SNP Annotation. 0.001) variants receiving priority. Finally, variants were filtered against 71 internal exome sequences called using the same pipeline. Determination of whether variants occurred in conserved sites or regions was assessed using GERP and PhastCons scores and the predicted functional significance of variants was analyzed using PolyPhen2. [16] [17] [18] As a complementary method for prioritization, variants were also analyzed using the VAAST, a probabilistic search instrument for analyzing function of variant gene sequences.
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VAAST has been shown to work well for rare Mendelian diseases; however, for more complex disorders, such as cancer, VAAST performance is still unclear. Candidate gene prioritization was performed under the autosomal dominant inheritance model using the default settings and making no assumptions about MAF or SNP novelty. As a background population for this analysis we used 71 internal exomes.
Validation of Exome Sequencing and Segregation Analysis
Candidate variants identified by exome sequencing and VAAST analysis were validated using bidirectional Sanger sequencing in the 3 patients with exome sequence data and tested for segregation in 14 additional affected and unaffected members of the kindred. Amplification and sequencing primers are shown in Supplementary Table 1. Genomic DNA was extracted from whole blood using a commercial kit according to manufacturer's instructions (QIAmp DNA Mini Kit, Qiagen, Germany). Pairwise estimates of relatedness were generated using KING 
Results

Characterization of the large family cohort with inherited DCM.
The proband (subject V-54; Figure 1 ) was a Caucasian male evaluated at age 40. He was recently diagnosed with DCM after presenting with chest discomfort, dyspnea and edema. The 
Exome Sequencing and Systematic Prioritization of Candidate Variants
A mean of 21. Table 2) .
Initial Filtering on Evolutionary Conservation and Predicted Deleteriousness Criteria
The initial variant prioritization strategy ( 
Filtering Strategy Using Internally-Generated Comparison Exomes
We next applied an alternative strategy by filtering the 26 rare or novel variants against 71 internal reference exome sequences (column 5, Figure 3 ). This step was intended to remove false positives related to our particular sequencing pipeline. All but 2 variants were present in multiple ( 2) internal exomes, suggesting that they are likely false positives ( Caucasian female with familial DCM. Neither the subject nor family members were accessible for evaluation, but available records showed that she was diagnosed at age 40 with severe leftventricular dysfunction (LVEF 10%) and there was an extensive history of cardiomyopathy and sudden death on the maternal side. Her mother had died from "heart disease" in her 40's, one brother had died from "myocarditis" at age 19, and a second brother was diagnosed with cardiomyopathy at age 39. Two maternal uncles were reported to have had sudden death in their 20's-30's. Estimates of kinship suggested no close relatedness of this subject ( rd degree relationship) to any of the three subjects with exome data (all pairwise kinship coefficients 0.01). Figure 3 demonstrates the incremental effects of adding subjects for exome sequencing and genetic distance between subjects for each step of systematic filtering. Column one shows the number of candidate variants at each step when only the proband is considered. Columns two, three and four show pairwise combinations of the three subjects from most closely related to While sequencing more remotely related individuals provides incremental improvement in filtering efficiency, a substantially larger effect is achieved by the addition of a third individual.
Effect of Relatedness and Number of Subjects Selected for Exome Sequencing
Under all combinations of subjects, the largest reduction in candidate variants is achieved by filtering for rarity against public and internal reference sequences.
VAAST Analysis
Using VAAST 19, 22 as a complementary method for variant prioritization under a dominant inheritance model returned a list of potential candidate genes and deleterious variants sorted according to statistical significance ( Table 3 ). The most likely causative genes according to VAAST analysis (ranked as equally likely statistically) were RBM20 and HDAC7 with the specific variants being c.1907 G>A (p.Arg636His), corresponding to that identified during systematic filtering, and a c.497 C>T (p.Arg166His) variant respectively. There was no reported clinical association, however this HDAC7 variant (rs148755202) has a minor allele frequency of 1.6% in the European American NHLBI Exome Sequencing Project 6500 dataset. The proband and subject V-11 were heterozygous for this variant and subject VI-1 (who underwent heart transplant at age 18) was homozygous at this site. variant was not confirmed in any of the three subjects, and therefore failed validation.
Sanger Validation of Exome Findings and Segregation in Pedigree
In total, 19 members of the kindred were identified as RBM20 p.Arg636His mutation carriers (8 by sequencing and 11 obligate carriers). Only 1 of the 17 mutation carriers for whom affection status was known did not meet criteria for DCM, and that subject was deemed indeterminate (CHF after age 50). Thus, the crude penetrance within this pedigree has a lower limit of 0.94 . Using all available family kinship and phenotype information, the maximum likelihood estimation of penetrance and credible 95% interval for this pedigree is 0.96 (0.85-1.0) (See Supplementary Table 3) . 23, 24 One subject (VI-1) had undergone heart transplantation (age 18). The mean age of death (N=11) or transplantation (N=1) was 46.1 ± 17.3 years. Among 8
clinically evaluated RBM20 mutation carriers, the mean age of diagnosis was 33.8 ± 11.5 years, and four of the eight were diagnosed in the 5 th decade of life (Table 4 ). 1
Discussion
Historical Context
RBM20 was definitively identified as a familial DCM gene in 2009. 25 This initial study reported 5 unique mutations, including the mutation identified in the current family, concentrated in a "hotspot" coded by exon 9, and the clinical description suggested an early onset and aggressive form of DCM. In that report, the p.Arg636His variant was identified in two related individuals of German origin. While the current family has lived locally for 7 generations, they are of European decent and it is possible that a common ancestor, and therefore a common founder mutation, is shared between the two pedigrees. Though precise pathologic mechanisms are incompletely understood, alterations in RNA splicing have been suggested 28 due to structural similarities of RBM20 to a family of proteins involved in this pathway. 25, 29 Supporting this hypothesis, a recent report has demonstrated a role for RBM20 in splicing regulation of the sarcomeric protein titin, and pathological alternate splicing has been demonstrated in a human RBM20 mutation carrier affected with DCM as well as in a rat model of RBM20
cardiomyopathy. 30 The prevalence of RBM20 mutations has since been reported as 1-3% among DCM cases. 31 At the time the proband of the current pedigree underwent genetic screening, RBM20
was not well established as disease-causing and thus was not included on commercial screening platforms.
WES has emerged as an important tool for genetic discovery. 8, 32 However, WES is subject to limitations. For example, it will not detect pathologic variants in regions not targeted by the capture strategy utilized, and insufficient coverage of targeted regions may lead to false negative findings. Conversely, false positives may result from incorrect short read mapping and errors related to sequencing technologies and variant calling pipelines. 33 Thus, identification of pathologic mutations from the hundreds of rare and private variants carried by every individual is often difficult.
14, 34
Extension of Clinical Characterization of RBM20 Cardiomyopathy
The current work adds to the clinical literature in important ways. First, this is largest pedigree to date of RBM20 related DCM. Moreover, the variant detected in this pedigree is representative in the sense that it has been described in two earlier reports and is located within the previously described hotspot. 25 The size of the pedigree allows accurate estimates regarding important This large pedigree confirms RBM20 related DCM as a highly penetrant, aggressive disease with high rates of heart failure and premature death. The mean age of diagnosis or detection in our pedigree was 33.8 ± 11.5 years and the mean age of death or transplantation for mutation carriers was 46.1 ± 17.3 years. These estimates are comparable to previous reports of pedigrees with RBM20 mutations (Table 4 ) 25, 26, 27 and highlight the aggressive nature and early mortality associated with this condition. The estimated penetrance in our pedigree was approximately 95%, a value similar to previously reported mutations within the RBM20 hotspot and other malignant monogenic DCM syndromes such as that associated with LMNA mutations. 35 Interestingly, in a previously published pedigree of RBM20 related DCM whose mutation is outside the hotspot 26 the estimated penetrance is lower at approximately 70% (Table 4) .
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Methodological Considerations: Importance of Phenotyped Internal Reference Exomes
This project further demonstrates the utility of WES for Mendelian disease gene discovery while simultaneously highlighting methodological difficulties and approaches to overcome them. As with all WES projects, a major analytical challenge is identifying causal mutations from the large number of potential variants. Our initial analysis utilized discrete filters based on genetic model (autosomal dominant), rarity, conservation scores, and predicted deleteriousness. After filtering using standard criteria, 8 candidate variants still remained. Table 4) ).
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should be very rare or novel, and commonness in internal exomes would likely signal an artifact of our pipeline. Indeed, most variants were found frequently among internal reference exomes, suggesting they were, in fact, false positives. Reference samples obtained locally are also more likely to represent regional ancestry and allele frequency patterns, and unlike most public databases, local sequences can be linked to accurate phenotypic data. This phenotype information allowed us to avoid removing the ostensibly very rare RBM20 variant because it was also found in a relatively small set of internal exomes, and instead positively prioritize the variant by noting that the only other occurrence was in a subject who also carried the phenotype of interest.
Methodological Considerations: Importance of Curated Pedigrees
Well-curated pedigrees improve confidence regarding inheritance pattern as well as relatedness and affection status of family members, especially those selected for exome analysis.
Furthermore, large pedigrees suggest a method of limiting the number of candidate variants through selection of remotely related individuals for sequencing. Because more remote relatives share smaller portions of their genomes, which presumably includes the causal variant, this method is predicted to substantially reduce the number of candidate variants. For example, the most remotely related pair of the three subjects with exome sequencing data (V-54 and VI-1) are predicted to share ~0.4% their genomes identical by descent. Sequencing of additional affected subjects should similarly reduce the number of candidates. Our results suggest that including 3 subjects in the analysis provides incremental benefit over including only 2 subjects, but the effect is less pronounced than when a second relative is added to the proband. The effect of relatedness was less pronounced with results including the two most distantly related individuals only slightly improved over analysis using the two most closely related subjects. For all combinations also carried the ph ph h hen en en eno fide e e en nce e e r reg g gar rdin ng g in n nhe he heri ri rita anc c ce e pat tte e ern n n a a as wel el el ell l l l a a as rela a at t ted on st tat at atus us us us o of fa fa f mi mi i ily ly ly m mem e be be bers s rs rs, espe e eci i ci cial al al all l ly t t t tho ho h h s se s s sel el el elec ec ect t te ted d d fo fo fo for r ex exo ome e e e an an analys ysi is is. Additionally, for investigators without access to high quality internal exomes, one may consider batching the sequencing and variant calling of several families into a single analysis so that they may serve as internal referencess for one another.
Methodological Considerations: Parallel Bioinformatic Prioritization
Finally, our study shows the utility of orthogonal methods for candidate prioritization. In our case, the primary technique was a heuristic of systematic filtering. Interestingly, VAAST analysis ascribed the highest probability of pathogenicity to the same variant derived by researcher-designed systematic filtering. The independent convergence of these methods help provided further confidence in the findings of systematic filtering.
Conclusion
WES is a powerful tool for identifying causal mutations in inherited cardiomyopathies
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No No No Norm rm rm rmal al al al Un Un Un Unkn kn kn know ow ow own n n n Un Un Un U kn kn kn know ow ow own n n n Un Un Un Unkn kn kn know ow ow own N N l l l 54 54% % 55 55 10 10 10/9 /9 /9 Subjects selected for exome sequencing are highlighted in red boxes. Carriers of the RBM20 mutation are marked with a plus sign (+). Genotyped subjects that are non-carriers of the RBM20 mutation are marked with a minus sign (-). 
